Blood Res.  2018 Mar;53(1):49-52. 10.5045/br.2018.53.1.49.

Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East

• Safaei A
• Monabati A
• Safavi M
• Atashabparvar A
• Hosseini M

• KMID: 2414364
• DOI: http://doi.org/10.5045/br.2018.53.1.49

Abstract

BACKGROUND
Additional cytogenetic aberrations are associated with disease progression in chronic myeloid leukemia (CML). This study was conducted to determine the type and frequency of these aberrations and their relationship with hematologic and molecular findings in the Middle East.
METHODS
In this retrospective study, 134 well-established cases of CML were selected from 2010 to 2016. Their hematologic phase and type of fusion gene were determined. Finally, their karyotypes were analyzed and reported according to ISCN 2013.
RESULTS
Patients had a mean age of 44 years. Twenty-two patients (16.4%) showed additional cytogenetic aberrations. Nine patients (6.7%) harbored a variant Philadelphia chromosome, and most were in the chronic phase. Seventeen patients (12.7%) had major and minor route abnormalities. There was a significant relationship between additional cytogenetic aberrations and major molecular response (P=0.032). Patient survival in the group with additional cytogenetic aberrations was significantly lower (49.7±11.1 mo) than that in the group without additional cytogenetic aberrations (77.3±3.1 mo) (P=0.031).
CONCLUSION
This study revealed the same frequency of additional cytogenetic aberrations in CML as found in previous studies. Additional chromosomal aberrations led to shorter survival and lower rates of achievement of a major molecular response.

Keyword

Chronic myeloid leukemia; Additional cytogenetic aberration; Variant Philadelphia chromosome

MeSH Terms

Chromosome Aberrations*
Cytogenetics*
Disease Progression
Humans
Karyotype
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Middle East*
Philadelphia Chromosome
Retrospective Studies

Figure

• 

  Fig. 1 Patients with additional cytogenetic aberrations (ACA) showed shorter survival.

Reference

1. Hehlmann R, Hochhaus A, Baccarani M. European LeukemiaNet. Chronic myeloid leukaemia. Lancet. 2007; 370:342–350. PMID: 17662883.

2. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000; 110:2–11. PMID: 10930974.

3. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004; 18:671–684. PMID: 15271399.

4. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007; 7:441–453. PMID: 17522713.

5. Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma. 2008; 49:610–614. PMID: 18398719.

6. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011; 118:6760–6768. PMID: 22039253.

7. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002; 107:76–94. PMID: 11919388.

8. Björk J, Albin M, Welinder H, et al. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med. 2001; 58:722–727. PMID: 11600728.

9. Syed NN, Usman M, Adil S, Khurshid M. Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2008; 1:166–170. PMID: 20063547.

10. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003; 17:481–487. PMID: 12646934.

11. Albano F, Specchia G, Anelli L, et al. Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. Genes Chromosomes Cancer. 2003; 36:353–360. PMID: 12619159.

12. El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004; 125:187–195. PMID: 15059141.

13. Eyüpoğlu D, Bozkurt S, Haznedaroğlu İ, Büyükaşık Y, Güven D. The impact of variant Philadelphia chromosome translocations on the clinical course of chronic myeloid leukemia. Turk J Haematol. 2016; 33:60–65. PMID: 27020722.

14. Marzocchi G, Castagnetti F, Luatti S, et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011; 117:6793–6800. PMID: 21447834.

15. Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012; 120:761–767. PMID: 22692507.